Polyglutamine diseases are a family of inherited neurodegenerative diseases caused by the expansion of CAG repeats within the coding region of target genes. Still the mechanism(s) by which polyglutamine proteins are ubiquitinated and degraded remains obscure. Here, for the first time, we demonstrate that Mahogunin 21 ring finger 1 E3 ubiquitin protein ligase is depleted in cells that express expanded-polyglutamine proteins. MGRN1 co-immunoprecipitates with expanded-polyglutamine huntingtin and ataxin-3 proteins. Furthermore, we show that MGRN1 is predominantly colocalized and recruits with polyglutamine aggregates in both cellular and transgenic mouse models. Finally, we demonstrate that the partial depletion of MGRN1 increases the rate of aggregate formation and cell death, whereas the overexpression of MGRN1 reduces the frequency of aggregate formation and provides cytoprotection against polyglutamine-induced proteotoxicity. These observations suggest that stimulating the activity of MGRN1 ubiquitin ligase might be a potential therapeutic target to eliminate the cytotoxic threat in polyglutamine diseases.
Introduction
A striking clinical hallmark of many neurodegenerative diseases is the presence of ubiquitin-positive intracellular inclusions formed by the aggregation of non-native neurotoxic proteins [1] [2] [3] . Numerous neurodegenerative diseases are caused by trinucleotide repeats, and polyglutamine diseases are caused by a (CAG) n expansion within the coding region of the responsible gene. Polyglutamine diseases such as Huntington's disease (HD), spinocerebellar ataxias (types 1, 2, 3, 6, 7 and 17) and X-linked spinal bulbar muscular atrophy (SBMA) are most likely caused by the neuronal dysfunction or neuronal cell death that results as the lengths of the glutamine stretches/repeats increase; early disease onset and the accumulation of intracellular aggregates are strongly linked with increased polyglutamine tract length [4] [5] [6] .
The question of whether the molecular pathology that underlies polyglutamine disease is caused by a gain or a loss of function is controversial. However, the formation of intraneuronal aggregates and the deposition of inclusion bodies represent a failure of the cellular protein quality control mechanism (QC). Currently, there are no known treatments that effectively prevent or eliminate aggregate formation in polyglutamine diseases. The ubiquitin proteasome system and the autophagy pathway are two molecular mechanisms responsible for eliminating misfolded or damaged proteins in the cell, and the failure of both of these mechanisms leads to neurodegeneration [7, 8] . Existing studies suggest that various chaperones, E3 ubiquitin ligases and other components of the proteasomal and autophagy degradation pathways are involved in the recognition and clearance of ubiquitin-positive intracellular aggregates [9] [10] [11] [12] [13] .
Studies suggest that a massive accumulation of misfolded proteins impairs proteasome function, e.g., the accumulation of expanded polyglutamine proteins leads to altered proteasomal function [14] [15] [16] . Thus, the molecular mechanism for cell survival under the noxious conditions generated by protein misfolding and the failure of the ubiquitin proteasome system are of interest. Evidence suggests that under proteotoxic threat, another misfolded-protein-elimination pathway, full condition autophagy, maintains the proteostasis in cells [17] [18] [19] . In mammalian cells, three different forms of autophagy have been described: macroautophagy, chaperone-mediated autophagy (CMA) and microautophagy [20] . Autophagy promotes the clearance of α-synuclein, expanded polyglutamine proteins and mutant SOD1 proteins, and the loss of autophagy causes neurodegenerative disease in mice [2, [21] [22] [23] [24] .
In the present work, we studied the detailed mechanism of the ubiquitination and degradation of expanded polyglutamine proteins by mahogunin ring finger-1 (MGRN1) E3 ubiquitin ligase through the autophagy pathway. The aberrant function of MGRN1 leads to lateonset spongiform neurodegeneration, and MGRN1 also interacts with cytosolic prion proteins (PrPs) that are linked with neurodegeneration [25, 26] . Here, we report that MGRN1 interacts with expanded polyglutamine proteins and recruits with ubiquitin and p62-positive expanded polyglutamine protein aggregates in both cellular and R6/2 transgenic mouse models. Moreover, MGRN1 is involved in the ubiquitination of expanded polyglutamine proteins; the overexpression of MGRN1 reduces polyglutamine-mediated cytotoxicity and prevents polyglutamine protein-induced cell death.
Materials and methods

Materials
Bafilomycin, 2-mercaptoethanol, TRIzol reagent, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), N6,2′-O-dibutyryladenosine-3′,5′-cyclic monophosphate (dbcAMP) and all cell culture reagents were obtained from Sigma. Lipofectamine 2000, optiMEM, plasmid pcDNA™ 3.1, ProLong® Gold Antifade Reagent, reverse transcription-polymerase chain reaction (RT-PCR) kits, Zenon®Alexa Fluor® 350 Mouse IgG1 labeling kits and Zenon®Alexa Fluor® 350 Rabbit IgG labeling kits were obtained from Life Technologies and Molecular Probes. Mouse monoclonal green fluorescent protein (GFP) antibody, nitroblue tetrazolium salt (NBT), BCIP (5-bromo-4-chloro-3-indolyl phosphate, toluidinium salt) and protein G-agarose beads were obtained from Roche Applied Science. iQ SYBR green super mix was from BioRad. Horseradish peroxidase-conjugated antirabbit, anti-goat and anti-mouse IgG was purchased from Amersham Biosciences. Alkaline phosphatase-conjugated anti-goat, anti-rabbit and anti-mouse IgG was purchased from Vector Laboratories. Antimouse IgG-fluorescein isothiocyanate and IgG-rhodamine and antirabbit IgG-fluorescein isothiocyanate and IgG-rhodamine were purchased from Vector Laboratories. Monoclonal anti-ubiquitin, polyclonal anti-GFP, polyclonal anti-MGRN1 (SC-160519), and monoclonal antiactin-and MGRN1-specific siRNA oligonucleotides were purchased from Santa Cruz Biotechnology. Polyclonal anti-MGRN1 (SAB2101478) and monoclonal-anti-p62/SQSTM1 were purchased from Sigma. Rabbit polyclonal anti-ubiquitin was purchased from Dako. pEGFP-Hsp70 (Addgene-15215), plasmid pcDNA3-EGFP (Addgene 13031), pcDNA3-cmyc (Addgene 16011), pEGFP-C1-Ataxin3Q28 (Addgene-22122) and pEGFP-C1-Ataxin3Q84 (Addgene-22123) were purchased from Addgene.
Cell culture, transfection and cell viability assay
Cos-7, A549 and 293T cells were maintained in DMEM (SigmaAldrich). All cells were supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin and were grown at 37°C in 5% CO 2 . For the various experiments, cells were plated into 6-well, 24-well and 96-well tissue culture plates before one day of transfection at a subconfluent density. Lipofectamine 2000 transfection reagent was used for all transfections, in combination with various expression vectors that were used according to the manufacturers' protocols. The transfection efficiency was 80%-90% in all experiments. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, as described previously [27] .
Co-immunoprecipitation and immunoblotting experiment
Cos-7 cells were transiently transfected with normal (ataxin-3(Q28) and EGFP-HDQ23) and expanded polyglutamine (ataxin-3(Q28) and EGFP-HDQ74) constructs along with the MGRN1 plasmid. After 24 h, the cells were washed with PBS and lysed on ice for 30 min with NP-40 lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40 and complete protease inhibitor cocktail). The cell lysates were prepared for immunoprecipitation by briefly sonicating before centrifugation for 15 min at 15,000 ×g at 4°C. For each immunoprecipitation experiment, approximately 200 μg of protein in 0.2 ml of NP40 lysis buffer was incubated with 5 μg of primary antibody. The total cell lysate of the immunoprecipitated samples was separated by SDS-polyacrylamide gel electrophoresis and processed for immunoblotting as described elsewhere [28, 29] . All primary antibodies were used at a 1:1000 dilution for immunoblotting except for GFP, which was used at a 1:2000 dilution.
Immunofluorescence techniques
Cos-7 cells were grown in two-well chamber slides and were transiently transfected with the appropriate plasmids. After transfection for 48 h, the cells were washed twice with phosphate-buffered saline, fixed with 4% paraformaldehyde in phosphate-buffered saline for 30 min, permeabilized with 0.5% Triton X-100 in phosphate-buffered saline for 5 min, washed extensively and then blocked with 5% nonfat skim milk in Tris-buffered saline-Tween 20 (TBST) [50 mM Tris, pH 7.5, 0.15 M NaCl, 0.05% Tween 20] for 1 h. In some triple-labeling experiments, primary antibodies of p62 and ubiquitin were incubated with Zenon®Alexa Fluor® kits according to the manufacturer's protocol. Primary antibody incubation was carried out overnight at 4°C. After incubation, the cells were washed several times with TBST, incubated with rhodamine-conjugated secondary antibody (1:500 dilution) for 1 h, washed several times and finally processed for mounting as described previously [30] . Mounted slides were observed using a fluorescence microscope, and digital images were assembled using Adobe Photoshop.
Immunofluorescence staining in R6/2 mouse model of HD
For immunofluorescence staining of MGRN1, ubiquitin and p62 in the control and transgenic mouse brain sections, paraffin-embedded sections from various brain regions were deparaffinized, subjected to antigen retrieval and then processed for staining as described previously [27, 31] . Appropriate FITC-and rhodamine-conjugated secondary antibodies were used to visualize expression, and all sections were mounted in ProLong® Gold Antifade Reagent (Life Technologies) before analysis of expression and colocalization. In each experiment, we used 12-week-old male R6/2 transgenic mice and control male littermates of same age; the CAG repeat sizes in the R6/2 transgenic mice were 134 CAGQ and 130Q. CAG repeat length of htt for each mouse was routinely determined by the almost same method described previously [32] to exclude the deviated repeat samples due to the instability of CAG repeat. PCR was performed with FAM-labeled primer 31329 (ATGAAGGCCTTC GAGTCCCTCAAGTCCTTC) and primer 33934 (GGCG GCTGAG GAAGCTGAGGA) followed by capillary electrophoresis with ABI 3130xl (Applied Biosystems) and analysis with Genescan software (Applied Biosystems). In immunofluorescence staining experiments we used 5 μm thick paraffin-embedded brain sections. All experiments involving mice were approved by the Animal Experiment Committee of the RIKEN Brain Science Institute.
Degradation assay, aggregate counting and statistical analysis
Cos-7 cells were plated in a 6-well tissue-cultured plate. After 24 h, the cells were transiently transfected with plasmids for the expanded polyglutamine proteins, with or without the MGRN1 plasmid. Fortyeight hours after transfection, the cells were chased with 15 μg/ml of cycloheximide for the different time periods indicated. Cells were collected at each time point, and samples were processed for immunoblotting using the GFP antibody. Expanded polyglutamine aggregate formation was observed and counted under a fluorescence microscope (∼ 400 transfected cells in each case). Cells retaining more than one aggregate were considered to have a single big inclusion. Statistical difference values are presented as mean ± SD. Statistical analysis between groups and intergroup comparisons were performed by using the Student's t test, and p b 0.05 indicated statistical significance. The cell viability was determined by the MTT assay as described previously [33] .
Reverse transcriptase (RT) PCR analysis, quantitative real time RT-PCR analysis and RNA interference (RNAi) experiments
Cells were transfected with normal and expanded polyglutamine plasmids and we achieved about 80%-90% transfection efficiency. After 48 h of transfection, most of the expanded polyglutamine transfected cells were positive for aggregate formation and same cells were used for total RNA isolation with TRIzol reagent. Then semiquantitative RT-PCR was carried out with an RT-PCR kit (Life Technologies). The RT-PCR analysis conditions were the same for both MGRN1 and β-actin: 30 min at 50°C for reverse transcription of RNA, an initial denaturation step at 94°C for 5 min and further cycling through 94°C for 30 s denaturation, 55°C for 45 s annealing, 72°C for 1 min, a final extension step at 72°C for 5 min and 5 min at 4°C to cool down the reaction. The cycle numbers were 34 for MGRN1 and 23 for β-actin. The sequences of the various primers were as follows: MGRN1F, 5′-ATGG GCTCCATTCTCAGC-3′;M G R N 1 R ,5 ′-GTTGCTGTTGTCGCTGTTCT-3′; ActinF, 5′-TGACGGGGTCACCCACACTGTGCCCATCTA-3′; and ActinR, 5′-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3′. The quantitative real time PCR for MGRN1 was performed by using iQ SYBR green super mix (BioRad) after cDNA synthesis from total RNA isolated from culture cells using TRIzol reagent. Reactions were normalized with 18S RNA as internal control and all reactions were carried out in triplicate with negative controls lacking the template DNA. The real time PCRs were done using an iCycler iQ real-time Thermocycler Detection System (Bio-Rad). MISSION® siRNA Universal Negative Control #1 (SIC001) was purchased from Sigma. MGRN1 siRNA (h): sc-92983 was obtained from Santa Cruz Biotechnology. Another set of MGRN1 predesigned siRNA was purchased from Sigma, sequence of MGRN1-siRNA (GGAUGACG AGCUGAACUUU; AAAGUUCAGCUCGUCAUCC). For RNAi experiments, EGFP-HDQ74-expressing cells were transiently transfected with either MGRN1-siRNA or Control-siRNA oligonucleotides according to the manufacturer's protocol. At various time intervals, as indicated, cell aggregate formation was counted under a fluorescence microscope. Some cells were collected and processed for RT-PCR and immunoblotting analysis. For the cell death assay, EGFP-HDQ74-expressing cells were transfected with MGRN1-siRNA or Control-siRNA oligonucleotides, and cell viability was measured by MTT assay.
Results
Misfolded and ubiquitinated expanded polyglutamine proteins dysregulated MGRN1 expression
Protein misfolding promotes the ubiquitination and degradation of expanded polyglutamine proteins; failure to clear these aggregated polyglutamine proteins causes neurodegenerative diseases (also referred to as polyglutamine diseases). To examine the effect of polyglutamine on endogenous MGRN1 levels, we transfected normal (ataxin-3(28Q) and EGFP-HDQ23-EGFP-tagged huntingtin exon 1 protein with 23 polyQ repeats) and expanded polyglutamine (ataxin-3(84Q) and EGFP-HDQ74-EGFP-tagged huntingtin exon 1 protein with 74 polyQ repeats) into A549 cells, as described elsewhere [34, 35] .
These cells form aggregates when they express polyglutamine proteins with expanded repeat lengths. We isolated total RNA from GFPpositive aggregated cells and performed RT-PCR analysis for MGRN1. To our surprise, a significant decrease in MGRN1 mRNA levels in the expanded polyglutamine ataxin-3(84Q) (Fig. 1A and C) and EGFP-HDQ74 ( Fig. 1B and D) expressing cells was observed. We have noticed approximately a 0.5-fold decrease in MGRN1 mRNA levels in the expanded polyglutamine expressing cells as compared with control cells (Fig. 1E ). Approximately 50-60% of cells were positive for aggregates ( Fig. 1F and G) and expressed normal or expanded polyglutamine proteins ( Fig. 1H and I) 48 h after transfection. Next we tested the endogenous levels of MGRN1 in normal and expanded polyglutamine expressing cells (Fig. 1J) . It is surprising to notice dysregulation in MGRN1 protein levels. We speculate that this is most likely due to sequestration of endogenous MGRN1 with expanded polyglutamine proteins. To confirm this hypothesis we performed filter trap assay with cell lysates obtained from expanded polyglutamine expressing cells. As expected, we observed major association of MGRN1 protein with insoluble aggregates of expanded polyglutamine proteins (Fig. 1K ). Based on the data shown in Fig. 1 , we hypothesized that aggregation of expanded polyglutamine proteins promotes their sequestration and that these events might compromise MGRN1 protein function in the expanded polyglutamine-expressing cells. To test this hypothesis, we overexpressed normal and expanded polyglutamine proteins in cells and performed immunoblotting analysis using a ubiquitin antibody. As shown in Fig. 2A and B, approximately N50% of the EGFP-HDQ74 and ataxin-3(84Q)-expressing cells formed GFP-positive aggregates, and the huntingtin proteins with 74Q repeats and the ataxin-3 proteins with 84Q repeats were ubiquitinated, whereas the proteins with normal glutamine repeats did not exhibit ubiquitination. To confirm our hypothesis, we used the same samples for an immunoblotting analysis of MGRN1. We further analyzed dysregulation in the endogenous levels of MGRN1 protein in cells that expressed ubiquitinated expanded polyglutamine proteins compared with the cells that expressed nonubiquitinated proteins with normal numbers of glutamine repeats (Fig. 2AandC) .
MGRN1 interacts with the N-terminal of truncated misfolded huntingtin and ataxin-3 with expanded polyglutamine tracts
Our preliminary results suggested that MGRN1 interacts with the mutant expanded polyglutamine proteins and that this may be one of the factors involved in the dysregulation of endogenous MGRN1. We speculated that a stochastic interaction between MGRN1 and expanded polyglutamine proteins likely leads to a huge depletion of MGRN1 at the site of localization or function. To confirm this assumption, we checked the interaction of MGRN1 with expanded polyglutamine proteins. First, we overexpressed normal (ataxin-3(28Q) and EGFP-HDQ23) or expanded polyglutamine (ataxin-3(84Q) and EGFP-HDQ74) constructs in cells. Same set of cells was co-transfected with the MGRN1 construct as shown in Fig. 2D . MGRN1 was strongly and specifically immunoprecipitated with the huntingtin (EGFP-HDQ74) and ataxin-3(84Q) compared with the huntingtin (EGFP-HDQ23) and ataxin-3(28Q). Fig. 2E shows the same samples as in Fig. 2Drespective ly, probed with anti-GFP. We performed a detailed immunoprecipitation study using different control experiments to confirm the strong interaction of MGRN1 with the N-terminals of expanded polyglutamine huntingtin and ataxin-3 proteins. We further transfected normal and expanded polyglutamine constructs of the N-terminals of huntingtin or ataxin-3 proteins. Cell lysates were immunoprecipitated with beads only (control) (Fig. 2F ) and normal IgG ( Fig. 2G and H) , and the blots were probed with anti-MGRN1 and anti-GFP antibodies as indicated in Fig. 2F , G and H. To further confirm the interaction of MGRN1 and expanded polyglutamine proteins, we pulled the cell lysates with MGRN1 antibody and blots were processed with anti-GFP (Fig. 2I ) and for the control experiment only the GFP expressed cell lysates were used to immunoprecipitate with the MGRN1 antibody and blot was detected with the GFP antibody (Fig. 2J) . These results confirmed our finding that MGRN1 strongly interacts with the N-terminals of huntingtin and ataxin-3 proteins with expanded polyglutamine tracts.
Association and recruitment of MGRN1 with polyglutamine aggregates
To examine whether the subcellular localization of endogenous MGRN1 is affected by polyglutamine aggregates, we transfected normal and expanded polyglutamine protein huntingtin (EGFP-HDQ23 (Fig. 3A) and EGFP-HDQ74) (Fig. 3B ) and ataxin-3 (ataxin-3(28Q) (Fig. 3E ) and ataxin-3(84Q)) (Fig. 3F ) constructs in cells. After transfection, cells were subjected to immunofluorescence staining using MGRN1 antibody. Endogenous MGRN1 was recruited with the huntingtin and ataxin-3 expanded polyglutamine aggregates in cells as shown in Fig. 3 . Next, we further co-transfected huntingtin (EGFP-HDQ23 and EGFP-HDQ74) and ataxin-3 (ataxin-3(28Q) and ataxin-3(84Q)) constructs with the MGRN1 plasmid. After 48 h of transfection, cells were subjected to immunofluorescence experiments using the anti-MGRN1 antibody. MGRN1 was localized to the cytoplasm with partial or diffuse staining in the nucleus of cells expressing normal numbers of glutamine repeats, shown in Fig. 3C (EGFP-HDQ23) , and Fig. 3G  (ataxin-3(28Q) ). However, MGRN1 was co-localized and associated with the aggregates of proteins with expanded polyglutamine repeats (J-K) Cells were co-transfected as described above with ataxin-3-GFP fusion normal (ataxin-3(Q28)) and expanded polyglutamine (ataxin-3(Q84)) and EGFP-HD (normal (EGFP-HDQ23) and polyglutamine-expanded (EGFP-HDQ74)) constructs. Forty-eight hours after transfection, the cells were collected and processed for immunoblotting with MGRN1and actin antibodies (J). Some cells were cotransfected Myc-MGRN1 plasmid. Same cell lysates were processed for filter-trap analysis by probing with anti-GFP, anti-MGRN1 and anti-Myc antibodies (K).
in EGFP-HDQ74-and ataxin-3(84Q)-expressing cells (Fig. 3D and H) . Control experiment (without secondary antibody) for recruitments of MGRN1 with expanded polyglutamine aggregates was performed with EGFP-HDQ23 and EGFP-HDQ74 expressing cells ( Supplementary  Fig. S1 ). To further confirm that the polyglutamine aggregates are positive for MGRN1, we performed triple-immunofluorescence staining. As shown in Fig. 4A , MGRN1 was present in the cytoplasm and had a diffuse localization or staining pattern with p62 and ubiquitin in EGFP-HDQ23-expressing cells with a normal number of glutamine repeats. Strikingly, MGRN1 recruits and co-localizes with p62 and ubiquitin double-positive aggregates of expanded polyglutamine proteins ( Fig. 4A and B, lower panel) . These results indicate a strong and specific interaction between MGRN1 and misfolded-expanded polyglutamine proteins or their aggregates.
Recruitment and co-localization of MGRN1 with p62 and ubiquitin into neuronal aggregates of mutant huntingtin in the brains of R6/2 transgenic mice
To confirm our current finding that MGRN1 interacts and associates with p62 and ubiquitin polyglutamine aggregates in cellular models, we examined the recruitment and co-localization of MGRN1 in the R6/2 transgenic mouse brain, which models HD onset. We compared the MGRN1 localization profiles in control and R6/2 mice. Immunofluorescence staining showed that in control mice, MGRN1 was predominantly expressed in the cytoplasmic compartment of cerebellar Purkinje cells and in cortical neurons. However, in R6/2 HD transgenic mice, MGRN1 was strongly recruited to neuronal p62-positive aggregates in cerebellar Purkinje cells and in cortical neurons (Fig. 5A and B) . To confirm the Fig. 2 . Ubiquitination of expanded polyglutamine proteins depletes the endogenous level of MGRN1 protein and interaction of MGRN1 with soluble misfolded normal and expanded polyglutamine proteins. (A) Ataxin-3 normal (ataxin-3(Q28)) and expanded polyglutamine (ataxin-3(Q84)) and EGFP-HD (normal (EGFP-HDQ23) and polyglutamine-expanded (EGFP-HDQ74)) plasmids were transiently transfected in 293T cells; 48 h after transfection, the cells were subjected to immunoblotting analysis using ubiquitin, GFP, MGRN1 and actin antibodies. (B) Aggregate formation in expanded polyglutamine-expressing cells transfected with (ataxin-3(Q84) and EGFP-HDQ74) constructs. Arrows indicate the formation of aggregates in the expanded polyglutamine expressing cells. (C) Quantification of endogenous MGRN1 levels collected from three independent experiments using NIH Image analysis software. Data were normalized using actin. Values are the mean ± SD. *p b 0.05 with respect to cells expressing proteins with normal numbers of glutamine repeats. (D-E) Transfection was used to overexpress Myc-MGRN1 and normal (EGFP-HDQ23) and polyglutamine-expanded (EGFP-HDQ74) and ataxin-3 normal (ataxin-3(Q28)) and expanded polyglutamine (ataxin-3(Q84)) constructs in Cos-7 cells. After 48 h of transfection, the cell lysates were processed for immunoprecipitation (IP) with a GFP antibody. Blots were sequentially probed with anti-MGRN1 (D) and anti-GFP (E). (F) Cell lysates were collected from ataxin-3 and EGFP-HD normal and expanded polyglutamine-expressing cells and processed for IP by beads alone (control-IP) and blots were developed by anti-MGRN1. (G-H) As described above some cell lysates were used immunoprecipitation (IP) with normal IgG and blots were probed with anti-MGRN1 (G) and anti-GFP antibodies (H). (I) Cells were transfected with normal (EGFP-HDQ23) and polyglutamine-expanded (EGFP-HDQ74) constructs and lysates were processed for IP by anti-MGRN1 and blots were developed with anti-GFP. (J) Cells were transfected with only GFP expressing construct and lysates were processed for IP with MGRN1antibody and blot was developed with GFP antibody. Immunoprecipitants were subject to immunoblotting analysis with the indicated antibodies. recruitment of MGRN1 with neuronal aggregates of mutant huntingtin in the R6/2 HD mouse model, we performed double-immunofluorescence staining studies using MGRN1 and ubiquitin antibodies. Analysis of these results showed that more than 70%-80% of the ubiquitin positive aggregates were co-localized and recruited with the MGRN1 protein in the different brain regions of the HD R6/2 transgenic mouse model ( Fig. 6A and B) . We further confirmed that these neuronal (NeuN) positive aggregates (Fig. 7A and B) were also positive for huntingtin staining and colocalize with MGRN1 and p62 inclusions in R6/2 transgenic mice brain (Fig. 7C and D) . We further performed the quantification of same samples and observed that the normal MGRN1 bearing neurons were decreased in HD R6/2 transgenic mouse model (Fig. 7EandF) .
MGRN1 promotes the ubiquitination of polyglutamine-expanded proteins
The overburden or massive production of misfolded proteins can impair the ubiquitin proteasome system [36] . To avoid such a drastic problem and to promote the clearance of toxic soluble misfolded intermediates, cells adopt another strategy, i.e., autophagy-mediated clearance [37] . In the current study, we noticed the deregulation and strong association of MGRN1 with expanded polyglutamine proteins, and therefore we posed the question: how does MGRN1 respond to expanded polyglutamine proteins and target them for elimination? We co-expressed truncated N-terminal huntingtin (EGFP-HDQ74) with wild-type MGRN1 or its catalytic inactive mutant MGRN1 (AVVA) form. As shown in Fig. 8A , we observed that the overexpression of the wild-type MGRN1 promotes the ubiquitination of EGFP-HDQ74 polyglutamine intermediates. To confirm this finding, we precipitated cell lysates from various experiments with GFP antibody, and blots were probed using an anti-ubiquitin antibody. We speculated that MGRN1 interaction with expanded polyglutamine proteins could induce their ubiquitination. To validate this assumption we processed immunoprecipitation in cells expressing expanded polyglutamine proteins using GFP antibody and blots were probed with ubiquitin antibody. Cell lysates obtained from expanded polyglutamine proteins were centrifuged at 10,000 ×g at room temperature for 5 min and the separated pellet and supernatant fractions were analyzed by immunoblotting with antibodies against GFP and MGRN1. In pellet samples, higher molecular protein complex of expanded polyglutamine proteins retained in stacking gel (Fig. 8B) . As shown in Fig. 8C , overexpression of wild-type MGRN1 caused a significant increase in the accumulation of ubiquitinated derivatives of EGFP-HDQ74 proteins. Bafilomycin, an autophagy inhibitor, also induces the accumulation of ubiquitinated EGFP-HDQ74 proteins (Fig. 8C, left panel) . Bafilomycin treatment caused massive aggregate formation and the accumulation of highmolecular-weight complexes of the expanded polyglutamine proteins, which suggests that polyglutamine aggregation is also cleared by the autophagy pathway (Fig. 8C, upper panel) . As earlier reported, MGRN1 enhances the proteasome-independent ubiquitination of tumor-susceptibility gene 101 (TSG101) [38] . ITCH is another E3 ubiquitin ligase, which induces the degradation of Deltex (DTX) via lysosomal 
(A-B) Cos-7 cells were transiently transfected with EGFP-HDQ23 (A) EGFP-HDQ74 (B) constructs and after 48 h of transfection, the cells were processed for immunofluorescence staining for MGRN1 (red) and normal and expanded polyglutamine expressions (green). (C-D) EGFP-HDQ23 (C) and EGFP-HDQ74 (D) expressing
Cos-7 cells were transiently transfected with Myc-MGRN1 plasmid. Thirty-six hours after transfection, cells were subjected to immunofluorescence staining with anti-MGRN1 (red). A rhodamine-conjugated secondary antibody was used to label MGRN1. Arrows indicate the recruitment of MGRN1 to the huntingtin aggregates. (E-F) Cos-7 cells were transiently transfected with ataxin-3-GFP fusion normal (E) (ataxin-3(Q28)) and expanded (F) polyglutamine (ataxin-3(Q84)) constructs. Post transfected cells were subjected to immunofluorescence staining for MGRN1 (red) and normal and expanded polyglutamine expressions (green). (G-H) Sub-confluent Cos-7 cells were plated into 2-well chamber slides and co-transfected with ataxin-3-GFP fusion constructs containing (ataxin-3(Q28)) (G) and (ataxin-3(Q84)) (H) polyglutamine constructs along with Myc-MGRN1 plasmid as indicated. After transfection, the cells were fixed in 4% paraformaldehyde and then processed for immunofluorescence with MGRN1 antibody. MGRN1 was visualized with rhodamine-conjugated secondary antibody (red). Arrows indicate the recruitment of MGRN1 to ataxin-3 aggregates. Scale bar, 20 μm.
pathway and colocalizes with endocytic vesicles [39] . Nedd4 (neuronal precursor cell-expressed, developmentally down-regulated gene 4) is a HECT-domain ubiquitin ligase, which enhances the degradation of α-synuclein by the endo-lysosomal pathway [40] . These studies also support our hypothesis that probably MGRN1 can promote the ubiquitination of expanded polyglutamine through the autophagy pathway. As shown in Fig. 8D and E, transiently transfected overexpressed wild-type MGRN1 overexpression decreases the levels of EGFP-HDQ74 expanded polyglutamine proteins, which can be prevented upon the addition of the autophagy inhibitor bafilomycin (Fig. 8F and G) . Earlier it has been shown that improper sequestration of MGRN1 with cytosolic prion proteins contributes in neurodegeneration and MGRN1 interacts with Hsp70 chaperone [25, 41] . Therefore it may be possible that MGRN1 targets expanded polyglutamine proteins anchored with Hsp70 chaperone and promotes their clearance from the dense cellular pool, however for better understanding in near future it needs further study in detail.
MGRN1 suppresses aggregate formation and polyglutamine-induced cell death
Because we observed that MGRN1 enhances the ubiquitination and elimination of expanded polyglutamine proteins, we wondered whether MGRN1 could affect polyglutamine protein aggregation and polyglutamine protein-induced cell death. Therefore, we cotransfected 293T cells with huntingtin (EGFP-HDQ74) and MGRN1 or MGRN1-siRNA. As shown in Fig. 9A , aggregate formation was decreased by the overexpression of MGRN1. However, the number of aggregates increased in cells transfected with MGRN1-siRNA. The overexpression of MGRN1 enhances the clearance of expanded polyglutamine proteins, and downregulation promotes the accumulation of polyglutamine proteins (Fig. 9B) . The overexpression of MGRN1 significantly suppresses aggregate formation in a concentration-dependent manner (Fig. 9C) . Interestingly, the suppression of aggregate formation and cytoprotective affect against ER and heat stress was more pronounced when MGRN1 was overexpressed along with Hsp70 ( Fig. 9E and G) . Quantitative data from cells transfected with MGRN1-siRNA in a concentrationdependent manner showed a dose-dependent increase in the rate of aggregate formation, confirming the effect of MGRN1 on polyglutamine aggregate formation (Fig. 9D) . The knockdown of the endogenous levels of MGRN1 also significantly induced death in polyglutamine (74Q)-expressing cells (Fig. 9F) . We further confirm the cumulative cytoprotective role of MGRN1 and Hsp70 under various stress conditions; therefore we exposed cells with ER and heat stress conditions and observed that Hsp70 overexpression alleviates cytotoxicity under different stress conditions (Fig. 9G) . Taken together, our data suggest that MGRN1 reduces the formation of aggregates of expanded polyglutamine proteins and protects cells from death mediated by the proteotoxic effects of polyglutamine proteins.
Discussion
Cells eliminate abnormal proteins with the help of a protein quality control mechanism (QC). Expanded polyglutamine proteins induced multifactorial deleterious events in cells. Numerous E3s, such as Gp78, E6-AP, CHIP, Parkin, Hrd1 and Malin, play a crucial role in the clearance of polyglutamine proteins, reducing their aggregate formation and alleviating poly (Q)-proteotoxicity [5, 31, [42] [43] [44] [45] . Here, we identified that mahogunin ring finger-1 (MGRN1), a putative E3 ubiquitin ligase, interacts with misfolded and ubiquitinated expanded polyglutamine proteins in a cellular model of HD. Additionally, we observed the recruitment and co-localization of MGRN1 ubiquitin ligase in various brain regions in the R6/2 transgenic mouse model of HD. Finally, we showed that overexpression of MGRN1 facilitates the elimination of misfolded polyglutamine proteins via autophagy and reduces aggregate formation and cell death in expanded polyglutamine-expressing cells.
The overburden of misfolded or non-native protein aggregation impairs the function of the ubiquitin proteasome system [36, 46] .However, how the accumulation or aggregation of polyglutamine proteins impairs the function of the ubiquitin proteasome system and contributes to the pathomechanism of the disease is still controversial [47] [48] [49] [50] [51] . Previous studies indicate that the aggregation of polyglutamine proteins significantly impairs the activity of the proteasome against stress-induced protein aggregation [27, 52] . However, we do not know how cells survive the proteasome dysfunction caused by massive polyglutamine protein aggregation. Thus, it is important to understand what other cellular factors or pathways are involved in cell survival and the mechanisms that inhibit polyglutamine-mediated cellular toxicity. Reports suggest that to avoid these noxious conditions and to eliminate the misfolded protein load, the cellular protein quality control mechanism (QC) adopts another survival strategy, i.e., autophagy-mediated clearance [37, 53, 54] . Neural precursor cells that express both developmentally downregulated protein 4 (NEDD4) and atrophin-interacting protein 4 (AIP4)/Itch E3 ubiquitin ligases promote the clearance of melanocytic transmembrane proteins (i.e., Melan-A/MART-1) by lysosomes [55] . MGRN1 is a ring finger-1 E3 ubiquitin ligase that is involved in spongiform neurodegeneration encephalopathy. Recently it has been observed that MGRN1 overexpression and loss of function do not influence prion disease; possibly functional sequestration of MGRN1 may cause cytosolic PrP linked neurotoxicity [56] . We have shown that MGRN1 overexpression reduces the aggregation of chaperone associated misfolded proteins in cells [41] . MGRN1 facilitates the ubiquitination and degradation of tumor-susceptibility gene 101 (TSG101) via the endolysosomal pathway [57] .
Earlier it has been proposed that cytosolic prion protein exposure disrupts the function of MGRN1 that contributes in neurodegeneration [25] . In our current study we have also observed that MGRN1 mRNA and protein levels were reduced in the poly (Q) expanded huntingtinand ataxin-3 fragment-expressing cells. Why were endogenous MGRN1 levels depleted in polyglutamine-expressing cells? Previous studies elaborate that the interaction of polyglutamine aggregates interrupts the normal function of various transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), CREB binding protein (CBP), TATA box binding protein (TBP) and specificity protein 1 (Sp1) [58] [59] [60] [61] [62] . Most probably sequestration and depleted function of these transcriptions contribute in the molecular pathomechanism of polyglutamine diseases. Overall these studies also support our current speculation that MGRN1 interacts with polyglutamine aggregated intermediate species for their clearance. It is possible that this interaction leads to the co-aggregation and sequestration of MGRN1 with the existing polyglutamine protein aggregates, and this prolonged mislocalization may lead to the depletion of MGRN1, most likely contributing to the pathogenesis of polyglutamine diseases. In the present study, we confirmed the interaction of MGRN1 with expanded polyglutamine proteins via a detailed coimmunoprecipitation study and observed the co-localization of MGRN1 with cellular aggregates of poly (Q) expanded huntingtin and ataxin-3 protein. Previously, malin E3 ubiquitin ligase was shown to associate with ubiquitinated Lafora bodies, and the loss of malin function most likely contributes to the pathogenesis of Lafora disease [63] . The malin E3 ubiquitin ligase study supports our current findings; to validate this novel interaction, we used triple-immunofluorescence analysis and report the co-localization of MGRN1 with p62 and ubiquitin-positive polyglutamine aggregates in cells.
Based on the interaction and co-localization of MGRN1 with expanded polyglutamine proteins in the cellular model of HD disease, we observed the recruitment of MGRN1 to the neuronal aggregates in R6/2 transgenic mice. In this mouse model of HD disease, we were able to detect a significant number of aggregates that were positive for MGRN1, p62 and ubiquitin staining and a clear redistribution of MGRN1 from the cytoplasm to the aggregates in the cerebellar Purkinje cells and cortical neurons. These results prompted us to investigate the functional role of MGRN1 in the elimination of expanded polyglutamine proteins and the consequent effect of this degradation on aggregate formation. We showed that autophagy inhibition induces the ubiquitination of expanded polyglutamine proteins. Induced autophagy retains an ability to reduce the toxicity of expanded polyglutamine proteins [64] . Our observations demonstrated that MGRN1 overexpression specifically stimulates the rate of degradation of the polyglutamine protein expansions and reduces aggregate formation, providing a cytoprotective response against polyglutamine-induced toxicity. This result was confirmed by the depletion of MGRN1 levels by siRNA, which increased the accumulation of expanded polyglutamine protein aggregates and enhanced the poly (Q) expansion-induced cell death. Interestingly, we noted that the protective response was more prominent when MGRN1 and the Hsp70 chaperone were co-expressed.
The identification of an E3 ubiquitin ligase that is capable of eliminating misfolded aggregated proteins represents a potential therapeutic approach against diseases caused by disordered proteins. There are numerous studies implicating autophagy or selective autophagy in polyglutamine diseases [65] [66] [67] . However, the detailed molecular function of autophagy in the selective recognition of expanded polyglutamine proteins is still not well understood. Our current study indicates that the recruitment of MGRN1 with expanded polyglutamine proteins occurs in cellular and mouse models of HD disease. Together, our results suggest that MGRN1 interacts with expanded polyglutamine proteins; the association of MGRN1 promotes the ubiquitination and elimination of poly (Q) expansions that eventually alleviate aggregation and cell death. MGRN1 provides cytoprotection against polyglutamine induced toxicity and probably its aberrant function plays a crucial role in the pathomechanism of neurodegeneration and possibly holds therapeutic potential for treating protein-disordered diseases.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.bbadis.2014.04.014.
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